Zevra Therapeutics Hits New 52-Week High of $13.79, Up 194.4%

Zevra Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.79 on June 9, 2026. This achievement underscores the company's robust performance, as it has demonstrated a remarkable 194.4% increase over the past year, significantly outperforming the S&P 500, which recorded a 22.99% gain during the same period. The company's financial metrics reflect strong operational health, with a price-to-earnings (P/E) ratio of 4.00 and a return on equity (ROE) of 89.05%. Zevra Therapeutics has also shown impressive growth in its operating profit, which surged by 392.61%, and a net profit of USD 52.5 million, marking a 227.97% increase. Additionally, the company has maintained positive results for five consecutive quarters, with operating cash flow reaching its highest at USD 12.77 million. With a market capitalization of USD 538 million and high institutional holdings at 82.89%, Zevra Therapeutics continues to demonstrate strong market performance and financial stability.